Published in Cancer Res on January 15, 1987
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II). Nucleic Acids Res (1989) 1.46
Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics (2007) 1.39
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer (2011) 1.39
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer (1998) 1.38
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene (2014) 1.20
Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer (1995) 1.16
Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer (2003) 1.16
Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res (2009) 1.15
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA. Mol Cell Biol (1991) 1.10
NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer (2009) 1.07
MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int (2012) 1.07
Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One (2012) 1.03
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. Nat Commun (2014) 1.00
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (2009) 0.96
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer (1993) 0.96
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther (2010) 0.95
Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci (2013) 0.94
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer (1997) 0.94
The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer (1990) 0.94
Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One (2014) 0.93
Anticancer and antimicrobial activities of some antioxidant-rich cameroonian medicinal plants. PLoS One (2013) 0.93
Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget (2014) 0.93
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest (1995) 0.92
Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis (2013) 0.91
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer (2014) 0.90
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer (2009) 0.89
DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Mol Cancer Res (2014) 0.89
Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer (1998) 0.89
β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res (2012) 0.88
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis (2015) 0.87
Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol (2013) 0.86
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol (2007) 0.86
Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts. Chem Res Toxicol (2009) 0.86
Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med (2012) 0.86
Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines. J Oncol (2010) 0.85
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep (2014) 0.85
Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol (1999) 0.85
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer (1993) 0.85
Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer (2002) 0.84
Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis. Cancer Med (2014) 0.84
Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS One (2013) 0.84
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer (2012) 0.84
Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett (2016) 0.83
The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J Biol Chem (2011) 0.83
Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br J Cancer (2004) 0.83
Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. ACS Nano (2016) 0.82
Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest New Drugs (2007) 0.82
Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer (1991) 0.82
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer (1995) 0.82
Enzyme-Regulated Supramolecular Assemblies of Cholesterol Conjugates against Drug-Resistant Ovarian Cancer Cells. J Am Chem Soc (2016) 0.81
Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. Br J Cancer (1994) 0.81
Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems. Front Oncol (2014) 0.81
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81
Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin. BMB Rep (2015) 0.81
Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci U S A (1994) 0.81
Effects of solvents on in vitro potencies of platinum compounds. DNA Repair (Amst) (2011) 0.81
Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells. Toxicol Sci (2014) 0.81
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One (2015) 0.80
Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity or resistance of human cells to ultraviolet radiation. Biochem J (1992) 0.80
NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells. Cancer Cell Int (2003) 0.80
Caspase-2 short isoform interacts with membrane-associated cytoskeleton proteins to inhibit apoptosis. PLoS One (2013) 0.79
Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro. Exp Ther Med (2011) 0.79
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer (2014) 0.79
Bioorthogonal small molecule imaging agents allow single-cell imaging of MET. PLoS One (2013) 0.79
Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes. Sci Rep (2016) 0.78
Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget (2016) 0.78
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer (2015) 0.78
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content. Glycoconj J (2012) 0.77
Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. Br J Cancer (2016) 0.77
Cisplatin-DNA damage recognition proteins in human tumour extracts. Br J Cancer (1993) 0.77
KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med (2009) 0.77
DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer (2015) 0.76
Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer (1998) 0.76
Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents. Nucleic Acids Res (2015) 0.76
Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res (2012) 0.76
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clin Cancer Res (2016) 0.76
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol (2016) 0.75
Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget (2017) 0.75
ct-DNA Binding and Antibacterial Activity of Octahedral Titanium (IV) Heteroleptic (Benzoylacetone and Hydroxamic Acids) Complexes. Int J Med Chem (2016) 0.75
DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res (2016) 0.75
Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy. Med Sci Monit (2017) 0.75
Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Oncotarget (2017) 0.75
Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis. Oncotarget (2016) 0.75
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
Ordered metal nanohole arrays made by a two-step replication of honeycomb structures of anodic alumina. Science (1995) 8.78
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation (2001) 4.17
Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures. Proc Natl Acad Sci U S A (1969) 3.72
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 2.75
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
[Methadone maintenance of HIV-infected drug addicts with immune deficiency]. Tidsskr Nor Laegeforen (1991) 2.57
Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol (1997) 2.38
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A (1988) 2.26
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med (1984) 2.22
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest (2001) 2.20
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Clinically defined vascular depression. Am J Psychiatry (1997) 2.06
Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet (1986) 2.04
Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res (2000) 2.04
Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol (1985) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
TB testing. Vet Rec (1996) 2.01
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy (2010) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A (1988) 1.86
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82
BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79
Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78
When overexpressed, a novel centrosomal protein, RanBPM, causes ectopic microtubule nucleation similar to gamma-tubulin. J Cell Biol (1998) 1.78
Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun (1998) 1.74
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol (1992) 1.69
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1985) 1.66
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet (1982) 1.61
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55